Conduction System Pacing Patents: Top Companies & Trends 2026
- One assignee dominates the ranking the leader holds 84 of the 140 records in scope, with the fifth-ranked company at only 7 and the tenth at 4 — a steep drop-off after the top position.
- Filings grew 65% from 2021 to 2024 from 17 to 28 in that span, with 2023 the peak year so far at 29; 2025-2026 figures are still filling in due to publication lag.
- Claims cluster tightly around electrotherapy every record in scope sits in A61N, while only 26.4% also touch A61B diagnosis/surgery claims — the surrounding disciplines are thin by comparison.
Filing growth compares 2021 (17 records) with 2024 (28) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field.
What the conduction system pacing patent record shows
Conduction system pacing — including left bundle branch pacing — has moved from a niche implantation technique to a claimed technology area with its own lead designs, depth-control tooling and capture-threshold monitoring methods. The search set spans 140 published records from 2015 through the 2026 cut-off, built around the core terms of lead penetration depth, capture threshold, septal anatomy, QRS narrowing, implant tooling and long-term lead stability.
Filing activity was negligible before 2017 and built steadily to a peak of 29 records in 2023, tracking the clinical adoption curve of left bundle branch pacing as an alternative to conventional biventricular pacing. Because publication typically lags filing by around 18 months, the 2025 and 2026 figures in any trend chart understate real filing activity for those years and should not be read as a slowdown.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 140-record set: how filing volume has moved year on year, and which IPC subclasses the claims actually sit in.
Filing trend, 2017-2026
Filings rose from zero in 2017 to a peak of 29 in 2023, with the 2021-to-2024 span alone showing 65% growth (17 to 28). The most recent one to two years are undercounted because of publication lag, not falling interest.
IPC subclass distribution
A61N (electrotherapy) covers all 140 records in scope, confirming the search is anchored correctly on pacing hardware and methods. A61B (diagnosis and surgery) appears in 26.4% of records, reflecting implant-guidance and sensing claims layered on top of the core pacing claim; A61M, B33Y, H01H and H01R each appear in only a handful of records, marking narrow but real adjacent filing activity in fluid-device integration, additive-manufactured components and electrical connectors.
Shares are the percentage of the 140 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Conduction System Pacing with Eureka
This page is one run against one query. Ask Eureka your own question about conduction system pacing and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative filing and most-cited prior art
Adaptive cardiac conduction system pacing therapy for multi-chamber devices
Adaptive cardiac conduction system pacing therapy for multi-chamber devices may monitor electrical activity of a patient's heart and select a cardiac conduction system pacing therapy pacing mode based on the monitored electrical activity. For instance, one or more metrics such as P-wave-to-R-wave interval and QRS complex width may be determined based on the monitored electrical activity, and one of an inhibited pacing mode, a ventricular fusion pacing mode, an atrioventricular synchronous pacing mode, and an atrial fibrillation pacing mode may be selected based on the determined one or more metrics.Filed by Medtronic, Inc.; published 2026-04-16. Illustrates the current filing frontier: adaptive mode-switching layered on top of conduction system pacing rather than novel lead hardware.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20210015390A1 | Method and apparatus for implantation of a pacing electrode | 37 |
| 2 | US11045653B1 | Multi-electrode leads, adapters, and methods for left bundle branch pacing with depth control | 20 |
| 3 | US20210015389A1 | Method and apparatus for implantation of a pacing electrode | 19 |
| 4 | US20220362558A1 | Ventricular conduction system pacing therapy control | 10 |
| 5 | US20200254248A1 | Systems and methods for selecting, positioning, and controlling cardiac resynchronization therapy (CRT) elect… | 6 |
| 6 | US20220226636A1 | Lead construction including alignable marker elements | 5 |
| 7 | US20210308458A1 | Cardiac conduction system engagement | 5 |
| 8 | US10729902B1 | Intraseptal multi-electrode cardiac pacemaker and methods of use thereof | 5 |
| 9 | US11911166B2 | Method and apparatus for implantation of a pacing electrode | 4 |
| 10 | WO2024089501A1 | Apparatus for monitoring conduction system pacing | 3 |
Citation counts favour older filings simply because they have had more time to be cited; treat this as a signal of influence within the corpus, not a ranking of current technical importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three patterns worth acting on before drafting new claims in this space.
One assignee holds the bulk of the record set
The leading assignee accounts for 84 of the 140 records in scope, with the fifth-ranked company down at 7 and the tenth at 4. Any freedom-to-operate check in lead-delivery or depth-control claims should start with that leader's portfolio before looking anywhere else.
Filing volume is still rising through the last complete year
Filings grew from 17 in 2021 to 28 in 2024, a 65% increase, with 2023 the peak year so far at 29. That is growth in claim density, not evidence that the space is used up — new entrants are still finding room to file.
Claims sit close to the core pacing category
Every record in scope falls in A61N, and only 26.4% of the 140 records also carry an A61B diagnosis/surgery class. The remaining adjacent classes — body-fluid devices, additive manufacturing, connectors — each cover a handful of records, suggesting most claim drafting is still happening inside the core electrotherapy category rather than spreading into adjacent hardware disciplines.
Collaboration is limited and concentrated
Only six co-assignee pairings appear across the set, and the strongest of them repeat the same small group of parties. That points to largely independent in-house filing rather than joint-venture or licensing-driven co-development in this niche.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to conduction system pacing, with the prior art for and against each one.
Who is filing, and who has slowed down
The ranked list is short — 17 companies — and drops off sharply after the leader, with recent-year momentum data showing most named parties filed nothing in the latest tracked year.
The dominant filer, but momentum has cooled
The top-ranked assignee holds 84 of the 140 records in scope — far ahead of the rest of the ranking — yet its own latest-year filings fell 75% year-on-year, down to 2. That combination of a deep existing portfolio and slower recent output is typical of a company defending occupied claim space rather than racing to expand it.
A thin second tier with several filers at zero in the latest year
The fifth-ranked assignee sits at 7 records and the tenth at 4 — a long tail rather than a clear second-place challenger. Several named assignees in the recent-momentum data show zero filings in the latest tracked year, including parties that had previously filed at a steady pace, which is consistent with either a pause in R&D output or filings still working through publication lag.
Named individuals and a university health network appear alongside corporates
The ranking includes individual named inventors and a university health network alongside the device manufacturers, and the strongest co-assignee pairs link a major manufacturer with individually-named co-filers. That pattern suggests some of this IP originates from academic or personal invention before being co-assigned commercially.
| Assignee | Recent year | YoY |
|---|---|---|
| Medtronic, Inc. | 2 | -75% |
| Cardiac Pacemakers, Inc. | 0 | — |
| PACESETTER INC | 0 | -100% |
| Biotronik SE & Co. KG | 0 | -100% |
| EAGLE POINT MEDICAL LLC | 0 | — |
| Sorin CRM | 0 | — |
| The Government of the United States of America, as represented by the Secretary of the Department of Health & Human Services | 0 | — |
| University Health Network | 0 | — |
Using this landscape for a real decision
The data points to where the claim space is crowded and where it is thin — the next step is testing a specific claim or design against it.
Check freedom-to-operate against the leader
With 84 of 140 records held by one assignee, any new lead-delivery or depth-control design should be checked against that portfolio first, not the ranking as a whole.
Run a freedom-to-operate check in EurekaTrack the under-claimed sub-areas
Depth-controlled tooling, capture-threshold feedback and septal anatomy mapping each show comparatively few records — worth monitoring for new entrants before committing to a claim strategy.
Set up monitoring in EurekaWatch for 2025-2026 filings still publishing
Because publication lags filing by roughly 18 months, recent momentum figures will shift upward as more 2025-2026 applications publish.
Track new publications in EurekaCommon questions about conduction system pacing patents
One assignee dominates this data set, holding 84 of the 140 records in scope, which is far ahead of every other party in the 17-company ranking. The fifth-ranked assignee holds only 7 records and the tenth holds 4, so the field has a steep drop-off after the leader rather than a cluster of close competitors. Anyone assessing competitive position or freedom-to-operate in lead-delivery or capture-threshold claims should treat that leader's portfolio as the primary reference point.
Yes, through the last complete year of data. Filings rose from 17 in 2021 to 28 in 2024, a 65% increase, with 2023 the single peak year so far at 29 records. Figures for 2025 and 2026 look lower only because publication typically lags filing by about 18 months — those years are still filling in, not evidence of a slowdown.
Every record in this set falls within A61N (electrotherapy and radiation therapy), which is expected given the search is anchored on pacing devices and methods. About a quarter of the records, 26.4%, also carry an A61B diagnosis-and-surgery classification, reflecting claims around implant guidance and sensing. Smaller numbers touch body-fluid devices, additive manufacturing and electrical connectors, but these adjacent categories each cover only a handful of the 140 records.
Based on the technology composition, adjacent sub-areas such as depth-controlled lead delivery tooling, real-time capture-threshold feedback during implant, septal anatomy mapping and additive-manufactured lead components show comparatively few records relative to the core electrotherapy category. That does not guarantee those areas are open, but the low record counts relative to the core A61N category suggest less-occupied claim space worth checking against the leader's specific claims before drafting.
A representative recent filing, US20260102622A1 from Medtronic, describes adaptive pacing-mode selection for multi-chamber devices based on monitored metrics like P-wave-to-R-wave interval and QRS complex width, switching among inhibited, ventricular fusion, atrioventricular synchronous and atrial fibrillation pacing modes. This shows the filing frontier moving toward adaptive control logic layered on top of established conduction system pacing hardware, rather than new lead or electrode designs. It is one data point, not the whole portfolio, but it illustrates where recent claim drafting is concentrated.
Research Conduction System Pacing in depth with Eureka
Go past this page: query the whole conduction system pacing corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.